Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
04 mars 2024 07h00 HE
|
Helius Medical Technologies, Inc.
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances...
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
06 févr. 2024 07h00 HE
|
Helius Medical Technologies, Inc.
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on...
Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS
05 févr. 2024 07h05 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) is expanding its presence at the 2024 American Physical Therapy Association (APTA) Combined Sections...
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
11 janv. 2024 07h00 HE
|
Helius Medical Technologies, Inc.
-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of patients to 100 -- -- Study uses Portable Neuromodulation Stimulator...
Helius Medical Technologies to Present at NobleCon19 Annual Conference
30 nov. 2023 07h47 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results
09 nov. 2023 16h05 HE
|
Helius Medical Technologies, Inc.
-- Cash runway extended into Q2 2024 ---- Company to host call at 4:30pm today -- NEWTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the...
Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work
06 nov. 2023 07h05 HE
|
Helius Medical Technologies, Inc.
-- Collaborative project between Pacific Blue Cross and HealthTech Connex designed to reduce long-term disability and improve quality of life for individuals suffering from traumatic brain injury...
Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024
02 nov. 2023 17h05 HE
|
Helius Medical Technologies, Inc.
-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 -- ...
Helius Medical Technologies, Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices
12 oct. 2023 07h05 HE
|
Helius Medical Technologies, Inc.
-- PoNS® devices to be provided to a least five sites in five separate administrative regions within Québec ---- Government-funded initiative will evaluate the benefits of PoNS Therapy™ when used by...
Helius Medical Technologies to Participate at Two Upcoming Healthcare Conferences
02 oct. 2023 07h05 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...